LeMaitre Q2 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Lemaitre Vascular (LMAT) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY24 Guidance
August 1, 2024 4:36 PM EDTLemaitre Vascular (NASDAQ: LMAT) reported Q2 EPS of $0.52, $0.05 better than the analyst estimate of $0.47. Revenue for the quarter came in at $55.8 million versus the consensus estimate of $54.98 million.
GUIDANCE:
Lemaitre Vascular sees FY2024 EPS of $1.82-$1.91, versus the consensus of $1.77.... More
